These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 28382636)

  • 1. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
    van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
    Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
    Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
    J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
    Pérez-Garcia J; Cortés J; Metzger Filho O
    Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer.
    Truin W; Voogd AC; Vreugdenhil G; van der Sangen MJ; van Beek MW; Roumen RM
    Breast; 2011 Dec; 20(6):505-9. PubMed ID: 21665471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
    Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
    PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
    Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.
    Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M
    Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study.
    Tan RYC; Ong WS; Lee KH; Park S; Iqbal J; Park YH; Lee JE; Yu JH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Koh J; Han W; Im SA; Tan VKM; Phyu N; Wong FY; Tan PH; Yap YS
    J Natl Compr Canc Netw; 2024 May; 22(2 D):. PubMed ID: 38744306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
    Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
    BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
    Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
    Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.